|
Showing 1 - 6 of
6 matches in All Departments
Universities were once ivory towers where scholarship and teaching
reigned supreme, or so we tell ourselves. Whether they were ever as
pure as we think, it is certainly the case that they are pure no
longer. Administrators look to patents as they seek money by
commercializing faculty discoveries; they pour money into sports
with the expectation that these spectacles will somehow bring in
revenue; they sign contracts with soda and fast-food companies,
legitimizing the dominance of a single brand on campus; and they
charge for distance learning courses that they market widely. In
this volume, edited by Donald G. Stein, university presidents and
others in higher education leadership positions comment on the many
connections between business and scholarship when intellectual
property and learning is treated as a marketable commodity. Some
contributors write about the benefits of these connections in
providing much needed resources. Others emphasize that the thirst
for profits may bias the type of research that is carried out and
the quality of that research. They fear for the future of basic
research if faculty are in search of immediate payoffs. The
majority of the contributors acknowledge that commercialization is
the current reality and has progressed too far to return to the
""good old days." They propose guidelines for students and
professors to govern commercial activities. Such guidelines can
increase the likelihood that quality, openness, and collegiality
will remain core academic values.
The Clash of Medical Evidence and the Law in the Breast Implant Case "An accessible, passionate indictment of the ignorance, opportunism and social indifference that enriched lawyers and a few plaintiffs, though the available scientific evidence was against them." —New York Times Book Review Notable Books of 1996
In the early 1990s, sympathetic juries awarded huge damages to women claiming injury from silicone breast implants, leading to a $4.25 billion class-action settlement that still wasn’t large enough to cover all the claims. Shockingly, rigorous scientific studies of breast implants have now shown that there is no significant link between breast implants and disease. Why were the courts and the public so certain that breast implants were dangerous when medical researchers were not? The answer to this question reveals important differences in the way science, the law, and the public regard evidence—and not just in the breast implant controversy.
"An indispensable guide to the breast implant madness—litigation that will forever stand as a monument to the inability of our civil justice system to sort out latter-day Ptolemies from Galileos."—Wall Street Journal
"[A] sober and rigorous examination of the controversy over silicone breast implants . . . an important statement, not just about silicone implants, but about other matters at the intersection of law, science, and opinion. [Dr. Angell’s] book is . . . a warning that rationality, like much else in the fragile porcelain of society, can be weakened by lack of vigilance."—New York Times
"Marcia Angell's outstanding book explains clearly and fairly the combination of greed, fear, ignorance, junk science, and media hype that created this national litigation nightmare. Everyone interested in the tort system, science, and medicine should heed the lessons that Dr. Angell teaches."—Shirley M. Hufstedler, former U.S. Secretary of Education and former judge in the U.S. Court of Appeals, 9th Circuit
During her two decades at "The" "New England Journal of Medicine,"
Dr. Marcia Angell had a front-row seat on the appalling spectacle
of the pharmaceutical industry. She watched drug companies stray
from their original mission of discovering and manufacturing useful
drugs and instead become vast marketing machines with unprecedented
control over their own fortunes. She saw them gain nearly limitless
influence over medical research, education, and how doctors do
their jobs. She sympathized as the American public, particularly
the elderly, struggled and increasingly failed to meet spiraling
prescription drug prices. Now, in this bold, hard-hitting new book,
Dr. Angell exposes the shocking truth of what the pharmaceutical
industry has become-and argues for essential, long-overdue change.
Currently Americans spend a staggering $200 billion each year on
prescription drugs. As Dr. Angell powerfully demonstrates, claims
that high drug prices are necessary to fund research and
development are unfounded: The truth is that drug companies funnel
the bulk of their resources into the marketing of products of
dubious benefit. Meanwhile, as profits soar, the companies brazenly
use their wealth and power to push their agenda through Congress,
the FDA, and academic medical centers.
Zeroing in on hugely successful drugs like AZT (the first drug to
treat HIV/AIDS), Taxol (the best-selling cancer drug in history),
and the blockbuster allergy drug Claritin, Dr. Angell demonstrates
exactly how new products are brought to market. Drug companies, she
shows, routinely rely on publicly funded institutions for their
basic research; they rig clinical trials to make their products
look better than they are; and they use their legions of lawyers to
stretch out government-granted exclusive marketing rights for
years. They also flood the market with copycat drugs that cost a
lot more than the drugs they mimic but are no more effective.
The American pharmaceutical industry needs to be saved, mainly from
itself, and Dr. Angell proposes a program of vital reforms, which
includes restoring impartiality to clinical research and severing
the ties between drug companies and medical education. Written with
fierce passion and substantiated with in-depth research, "The Truth
About the Drug Companies" is a searing indictment of an industry
that has spun out of control.
"From the Hardcover edition."
The art of the Angels is God's symmetry
Use Angelic art to inspire higher expression of your ideas, ideals,
dreams and visions
Angel art is art that prepares us for holidays and holiday
inspiration.
|
You may like...
Poor Things
Emma Stone, Mark Ruffalo, …
DVD
R343
Discovery Miles 3 430
|